Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection

Andrew, Peter; Birch, Helen; Phillpot, Deborah A.

doi:10.1002/jps.2600820116

Cited by 52 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples for sumatriptan and growth hormone (GH) plasma level determination were drawn at the same time points. Sumatriptan was analyzed using high performance liquid chromatography (Andrew et al 1993). GH was assayed using a commercially available radioimmunoassay (RIA) kit (Oris Industry Company Gif-sur Yvette, France), which had a lower limit of detection of 0.5 mU / I.…”

Section: Methodsmentioning

confidence: 99%

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Pian¹,

Westerberg²,

Megen³

et al. 1998

Psychopharmacology

View full text Add to dashboard Cite

The non-selective serotonin (5-HT) receptor agonist meta-chlorophenylpiperazine (mCPP) has been reported to elicit symptoms in patients with obsessive compulsive disorder (OCD). MK-212, another non-selective 5-HT receptor agonist, does not seem to induce obsessive compulsive symptoms in OCD patients. The major pharmacological difference between mCPP and MK-212 is their affinity for the 5-HT(ID) receptor. The aim of this study was to explore the role of the 5-HT(ID) receptor in the pathophysiology of OCD, by using a challenge paradigm with the selective 5-HT(ID) receptor agonist sumatriptan (Imigran). A randomized, double-blind, placebo-controlled crossover challenge with sumatriptan (100 mg PO) was performed in 15 OCD patients. Neither the obsessive compulsive symptoms nor mood or anxiety symptoms changed significantly following sumatriptan administration as compared to placebo. Sumatriptan did induce a significant increase in plasma growth hormone (GH) levels. In the present study, no indication were found for the role of the 5-HT(ID) receptor in the pathophysiology of OCD. It should be noted, however, that sumatriptan does not readily pass the blood-brain barrier. Selective 5-HT(ID) receptors with better brain penetrating properties may shed more light on the role of this 5-HT receptor subtype in OCD.

show abstract

Section: Methodsmentioning

confidence: 99%

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Pian¹,

Westerberg²,

Megen³

et al. 1998

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Assay of plasma, serum and urine samples for sumatriptan base was carried out using a validated high performance liquid chromatographic (HPLC) method with electrochemical detection [8]. The lower limit of quantification for the HPLC method was 1 ng• m1-1 from i ml of sample (plasma and serum).…”

Section: Methodsmentioning

confidence: 99%

Single dose pharmacokinetics of sumatriptan in healthy volunteers

Lacey¹,

Hussey

Fowler³

1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Sumatriptan is classified as a vascular 5HT1 receptor agonist and is effective in the acute treatment of migraine and cluster headache. Sumatriptan is available as an injection for subcutaneous administration and as a tablet for oral administration. The pharmacokinetics of sumatriptan differ depending on the route of administration. The mean subcutaneous bioavailability is 96% compared to 14% for the oral tablet. The lower bioavailability following oral administration is due mainly to presystemic metabolism. The inter-subject variability in plasma sumatriptan concentrations is greater following oral administration and a faster rate of absorption of drug into the systemic circulation is achieved following subcutaneous dosing. The pharmacokinetics of sumatriptan are linear up to a subcutaneous dose of 16 mg. Following oral dosing up to 400 mg, the pharmacokinetics are also linear, with the exception of rate of absorption, as indicated by a dose dependent increase in time to peak concentration. Sumatriptan is a highly cleared compound that is eliminated from the body primarily by metabolism to the pharmacologically inactive indoleacetic acid analogue. Both sumatriptan and its metabolite are excreted in the urine. Although the renal clearance of sumatriptan is only 20% of the total clearance, it exceeds the glomerular filtration rate, indicating that sumatriptan undergoes active renal tubular secretion. Sumatriptan has a large apparent volume of distribution (170 l) and an elimination half-life of 2 h. Oral doses of sumatriptan were administered as a solution of dispersible tablets and subcutaneous dosing was by injection into the arm. In clinical practice, sumatriptan is administered as a film coated tablet or by subcutaneous injection into the thigh.

show abstract

“…Liquid-liquid extraction (McLoughlin et al, 1996;Andrew et al, 1993) was necessary and important because it purified and also concentrated the sample. Ethyl acetate, methylene chloride and ether were all tested for extraction and ether was finally adapted because of its high extraction efficiency.…”

Section: Preparation Of Plasma Samplesmentioning

confidence: 99%

Liquid chromatography–mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study

Zhang

Xiang

Wang

2007

Biomedical Chromatography

View full text Add to dashboard Cite

A sensitive and selective liquid chromatographic-mass spectrometric (LC-MS) method for the determination of venlafaxine in human plasma has been developed. Samples were prepared using liquid-liquid extraction and analyzed on a C(18) column interfaced with a triple quadrupole mass spectrometer. Positive electrospray ionization was employed as the ionization source. The mobile phase was methanol-water containing 10 mmol/L ammonium acetate, pH 7.9 adjusted with aqueous ammonia (80:20, v/v) at the flow rate of 1.0 mL/min. The analyte and internal standard clozapine were both detected by use of selected ion monitoring mode. The method was linear in the concentration range of 1.0-200.0 ng/mL. The lower limit of quantification (LLOQ) was 1.0 ng/mL. The intra- and inter-day relative standard deviation across three validation runs over the entire concentration range was less than 10.1%. The accuracy determined at three concentrations (5.0, 50.0 and 150.0 ng/mL for venlafaxine) was within +/-10.0% in terms of relative error (RE). The method was successfully applied for the evaluation of pharmacokinetic profiles of venlafaxine capsule in 20 healthy volunteers. The results show AUC, T(max), C(max) and T(1/2) between the testing formulation and reference formulation have no significant difference (p > 0.05). Relative bioavailability was 103.4 +/- 14.1%.

show abstract

Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection

Cited by 52 publications

References 0 publications

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Sumatriptan (5-HT 1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder

Single dose pharmacokinetics of sumatriptan in healthy volunteers

Liquid chromatography–mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study

Contact Info

Product

Resources

About